Clinical Trial Update: Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing a Phase 1/2 study of Quaratusugene ozeplasmid (Reqorsa) in combination with atezolizumab maintenance therapy for extensive-stag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Reqorsa (Quaratusugene ozeplasmid)

Snippet

Sponsor: Genprex, Inc. | Conditions: Small Cell Lung Cancer Extensive Stage | Phase 1, Phase 2 | Status: RECRUITING